Clinical Trials Logo

Filter by:
NCT ID: NCT00684710 Completed - Healthy Clinical Trials

Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese Subjects

Start date: April 2008
Phase: Phase 1
Study type: Interventional

This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of PAZ-417 after administration of ascending single oral doses to healthy young Japanese male and healthy elderly Japanese male subjects.

NCT ID: NCT00684632 Completed - Pain, Cancer Clinical Trials

A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients

Start date: March 2008
Phase: Phase 3
Study type: Interventional

This study is designed to determine whether KW-2246 is superior to placebo and not inferior to immediate-release morphine for the relief of breakthrough pain in cancer patients.

NCT ID: NCT00683995 Completed - Pain, Cancer Clinical Trials

A Phase III Clinical Study of KW-2246

Start date: March 2008
Phase: Phase 3
Study type: Interventional

This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.

NCT ID: NCT00683904 Completed - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer

Start date: June 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose, dose-limiting toxicity, and recommended Phase II dose of ixabepilone in combination with carboplatin in patients with non-small cell lung cancer.

NCT ID: NCT00681577 Completed - Gastric Cancer Clinical Trials

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides URLC10, KOC1, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.

NCT ID: NCT00681551 Completed - Brain Neoplasms Clinical Trials

Magnevist (SH L 451A) Intra-individual Dose Comparison Study in Patients With Brain Metastasis

Start date: February 2003
Phase: Phase 3
Study type: Interventional

To verify the number of metastatic brain tumors detected in contrast-enhanced MRI, which is the primary variable, increases after an additional dose of Magnevist (SH L 451A) comparing images after an initial dose (0.1 mmol/kg) with those after an additional dose (0.1 mmol/kg, a total dose of 0.2 mmol/kg) intra-individually in patients with metastatic brain tumors. Safety was also to be assessed.

NCT ID: NCT00681421 Completed - Esophageal Cancer Clinical Trials

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.

NCT ID: NCT00681330 Completed - Esophageal Cancer Clinical Trials

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and time to progression of HLA-A*2402 restricted epitope peptides URLC10, TTK, and KOC1, emulsified with Montanide ISA 51.

NCT ID: NCT00681252 Completed - Gastric Cancer Clinical Trials

Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer

Start date: May 2008
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and time to progression of HLA-A*0201 restricted epitope peptides URLC10, VEGFR1 and VEGFR2 emulsified with Montanide ISA 51.

NCT ID: NCT00680953 Completed - Osteoporosis Clinical Trials

Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis

DIRECT
Start date: May 2008
Phase: Phase 3
Study type: Interventional

Evaluate the efficacy and safety of denosumab in the treatment of involutional (postmenopausal and senile) osteoporotic subjects with prevalent fragility vertebral fracture(s)